David Chan, a veteran of subadvisor Jennison Associates and lead manager of PGIM Jennison Health Sciences since the fund's 1999 inception, will step down and retire from the firm at the end of June 2022. Given the depth and experience of Jennison's healthcare team, Chan's departure is not detrimental to the strategy. It remains under the watch of industry veterans Debra Netschert and Daniel Matviyenko, who have comanaged the strategy since 2015 and 2020, respectively. With some continuity in the management ranks and no anticipated changes to the well-established approach, the strategy's Morningstar Analyst Ratings are unchanged.
PGIM Jennison Health Sciences Z PHSZX
Premium
Morningstar’s Analysis
The Morningstar Analysis section contains a thorough evaluation of an investment’s merits and drawbacks and often discusses the most important or decisive factors leading to the fund’s overall rating.
The Morningstar Analysis section contains a thorough evaluation of an investment’s merits and drawbacks and often discusses the most important or decisive factors leading to the fund’s overall rating.
Will PHSZX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
Process Pillar
The Process Pillar is our assessment of how sensible, clearly defined, and repeatable PHSZX’s performance objective and investment process is for both security selection and portfolio construction.
People Pillar
The People Pillar is our evaluation of the PHSZX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of PHSZX’s parent organization’s priorities and whether they’re in line with investors’ interests.
PGIM Jennison Health Sciences' Longtime Manager to Retire in June 2022; Ratings Unchanged
